Despite an enormous potential market, many Biotech companies have shied away from R&D funding related to drug and alcohol addiction.
Your firm, D&S, is a notable exception. It has spent 200 million to date working on a cure, but is now at a crossroads. It can either abandon its program or invest another $60 million today. Your opportunity cost of funds is 5%; unfortunately, it will take another five years before final approval from the Food and Drug Administration is achieved and the product is actually sold. Expected year–end profits are shown in the following diagram. Should D&S continue with the plan to bring the drug to market or should it abandon its plan?
Discuss the relevance, if any, of the $200 million expenditure, to the decision to continue with the program.
$200 million expenditure before today is sunk cost and will not used in further economic analysis
present cost = 60 m
i = 5%
We will use formula P = F/(1+i)^t to find present value of future cash flow
NPV of the project = -60m + 12m/(1+0.05)^5 + 13.4m/(1+0.05)^6 + 17.2m/(1+0.05)^7 + 20.7m/(1+0.05)^8 + 22.45m/(1+0.05)^9
= -60m + 12m/(1.05)^5 + 13.4m/(1.05)^6 + 17.2m/(1.05)^7 + 20.7m/(1.05)^8 + 22.45m/(1.05)^9
= 0.107364m
NPV is positive
So project should continue with investment of 60 m
Despite an enormous potential market, many Biotech companies have shied away from R&D funding related to...
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm – Drug Abuse Sciences (DAS) – is a notable exception. It has spent $230 million to date working on a cure, but...
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm – Drug Abuse Sciences (DAS) – is a notable exception. It has spent $230 million to date working on a cure, but...
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm - Drug Abuse Sciences (DAS) - is a notable exception. It has spent $235 million to date working on a cure, but...
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm – Drug Abuse Sciences (DAS) – is a notable exception. It has spent $185 million to date working on a cure, but...
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm - Drug Abuse Sciences (DAS) - is a notable exception. It has spent $280 million to date working on a cure, but...
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm – Drug Abuse Sciences (DAS) – is a notable exception. It has spent $160 million to date working on a cure, but...
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm – Drug Abuse Sciences (DAS) – is a notable exception. It has spent $280 million to date working on a cure, but...
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the . U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm Drug Abuse Sciences (DAS) is a notable exception. It has spent $215 million to date working on a cure, but is...
Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm – Drug Abuse Sciences (DAS) – is a notable exception. It has spent $245 million to date working on a cure, but...
Chapter 1 Problems Saved Help Save & Exit Submit Check my work 15 Approximately 14 million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction. Your firm Drug Abuse Sciences (DAS)- is a notable exception. It...